IMUX Stock Price, Immunic Inc Quote, Chart

Market Summary

USD1.21-0.07

Market Closed

-5.47%

IMUX Stock Price

View Fullscreen

IMUX RSI Chart

IMUX Valuation

Market Cap

108.8M

Price/Earnings (Trailing)

-1.16

Price/Sales (Trailing)

3.3

Price/Free Cashflow

-1.53

IMUX Price/Sales (Trailing)

IMUX Profitability

Return on Equity

-323.57%

Return on Assets

-172.4%

Free Cashflow Yield

-65.4%

IMUX Fundamentals

IMUX Revenue

Revenue (TTM)

17.3M

IMUX Earnings

Earnings (TTM)

-93.6M

Earnings Growth (Yr)

61.8%

Earnings Growth (Qtr)

5.26%

Breaking Down IMUX Revenue

Last 7 days

-12.2%

Last 30 days

-6.9%

Last 90 days

2.5%

Trailing 12 Months

-24.7%

How does IMUX drawdown profile look like?

IMUX Financial Health

Current Ratio

2.12

IMUX Investor Care

Shares Dilution (1Y)

102.53%

Diluted EPS (TTM)

-2.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	0	0	0	17.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Immunic Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 26, 2024	vitt daniel	bought	18,333	1.3095	14,000	president and ceo
May 15, 2023	whaley glenn	bought	8,750	1.75	5,000	chief financial officer
Dec 14, 2022	neermann joerg	bought	59,032	1.256	47,000	-
Dec 13, 2022	neermann joerg	bought	43,610	1.246	35,000	-
Nov 23, 2022	neermann joerg	bought	25,020	1.39	18,000	-
Nov 22, 2022	vitt daniel	bought	10,799	1.3499	8,000	president and ceo
Nov 07, 2022	whaley glenn	bought	7,475	1.495	5,000	chief financial officer
Jun 03, 2022	whaley glenn	bought	10,657	3.045	3,500	chief financial officer
Jun 03, 2022	vitt daniel	bought	15,499	3.0999	5,000	president and ceo
May 12, 2022	nash duane	gifted	-	-	-6,000	executive chairman

Which funds bought or sold IMUX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 28, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	15.00	750	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.71	92,495	2,536,500	-%
Feb 22, 2024	SIERRA SUMMIT ADVISORS LLC	new	-	487,244	487,244	0.14%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-17.57	-24,607	130,319	-%
Feb 14, 2024	UBS OCONNOR LLC	reduced	-21.2	-219,329	900,351	0.06%
Feb 14, 2024	WOLVERINE TRADING, LLC	new	-	16,388	16,388	-%
Feb 14, 2024	GROUP ONE TRADING, L.P.	sold off	-100	-629	-	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	3,775	188,705	-%
Feb 14, 2024	Royal Bank of Canada	added	326	-	-	-%
Feb 14, 2024	BVF INC/IL	sold off	-100	-1,689,660	-	-%

Are Funds Buying or Selling IMUX?

Are funds buying IMUX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMUX

No. of Funds

Unveiling Immunic Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	commodore capital lp	0.0%	0	SC 13G/A
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.6%	4,335,255	SC 13G/A
Jan 18, 2024	biotechnology value fund l p	5.2%	4,665,158	SC 13G
Jan 18, 2024	janus henderson group plc	7.4%	6,693,007	SC 13G
Jan 16, 2024	avidity partners management lp	9.9%	8,899,418	SC 13G
Jan 10, 2024	soleus private equity fund iii, l.p.	5.4%	4,895,105	SC 13G
Feb 24, 2023	lsp v cooperatieve u.a.	4.9%	2,162,782	SC 13D/A
Feb 14, 2023	commodore capital lp	6.3%	2,873,563	SC 13G/A
Feb 14, 2023	deep track capital, lp	8.32%	4,022,989	SC 13G/A

Recent SEC filings of Immunic Inc

View All Filings

Date Filed	Form Type	Document
Mar 08, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading
Mar 01, 2024	S-3/A	S-3/A

Peers (Alternatives to Immunic Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Immunic Inc News

Latest updates

Immunic Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	-	17,250,000
Operating Expenses	18.1%	21,721,000	18,387,000	19,170,000	32,387,000
S&GA Expenses	15.0%	3,343,000	2,907,000	3,432,000	3,618,000
R&D Expenses	18.7%	18,378,000	15,480,000	15,738,000	11,519,000
EBITDA Margin	-Infinity%	-2.40	-	-1.20	-
EBT Margin	-Infinity%	-2.40	-	-1.20	-
Net Income	-9.8%	-21,185,000	-19,292,000	-17,934,000	-34,534,000
Net Income Margin	-Infinity%	-5.39	-	-	-
Free Cashflow	-34.5%	-23,700,000	-17,619,000	-29,023,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.9%	54.00	67.00	89.00	109	128	121	139	150	139	157	136	155	168	172	87.00	57.00	66.00	68.00	73.00	10.00	13.00
Current Assets	-19.5%	53.00	65.00	87.00	107	126	87.00	105	116	105	122	102	120	134	138	53.00	24.00	32.00	35.00	39.00	10.00	13.00
Cash Equivalents	-21.8%	47.00	60.00	77.00	93.00	107	73.00	88.00	96.00	87.00	110	87.00	115	127	133	49.00	19.00	29.00	30.00	36.00	8.00	13.00
Net PPE	61.8%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	-
Liabilities	36.6%	25.00	19.00	19.00	18.00	14.00	12.00	11.00	12.00	12.00	11.00	15.00	17.00	9.00	9.00	8.00	7.00	8.00	7.00	3.00	-	2.00
Current Liabilities	39.1%	25.00	18.00	18.00	16.00	13.00	12.00	10.00	11.00	11.00	11.00	14.00	16.00	8.00	8.00	8.00	6.00	7.00	7.00	3.00	1.00	2.00
Shareholder's Equity	-40.2%	29.00	48.00	69.00	91.00	114	109	128	138	127	145	121	137	159	163	79.00	50.00	58.00	61.00	69.00	9.00	12.00
Retained Earnings	-5.5%	-410	-389	-366	-342	-317	-260	-239	-217	-196	-175	-156	-138	-103	-92.80	-79.90	-68.40	-59.91	-52.22	-44.00	-346	-25.00
Additional Paid-In Capital	0.5%	436	434	432	430	428	370	368	356	324	322	279	277	267	257	160	121	120	115	114	356	0.00
Shares Outstanding	1.3%	45.00	45.00	44.00	44.00	39.00	31.00	29.00	28.00	26.00	22.00	21.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	110	-	-	-	106	-	-	-	225	-	-	-	181	-	-	-	51.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.0%	-14,027	-17,312	-19,976	-19,513	-15,104	-13,596	-15,763	-20,681	-23,681	-17,599	-29,005	-12,948	-13,963	-11,905	-9,227	-11,029	-6,265	-5,976	-10,987	-5,317	-3,445
Share Based Compensation	-2.9%	1,638	1,687	1,798	1,979	1,886	1,912	2,062	2,069	1,466	1,397	1,507	1,579	1,318	707	369	353	330	199	5,983	-	-
Cashflow From Investing	-275.0%	-165	-44.00	4,336	5,335	-9,628	-73.00	-28.00	-12.00	-19.00	-20.00	-18.00	-10.00	-24.00	-63.00	-55.00	-4.00	-25.00	1,237	9,331	-7.00	-20.00
Cashflow From Financing	114.2%	604	282	96.00	51.00	56,041	-	10,076	29,643	821	42,020	-	-	8,111	96,540	39,212	568	4,707	223	9,434	20,531	6,692

IMUX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 83,215	$ 71,255
General and administrative	16,008	15,263
Goodwill impairment (see Note 2)	0	32,970
Total operating expenses	99,223	119,488
Loss from operations	(99,223)	(119,488)
Other income (expense):
Interest income	3,075	1,041
Other income (expense), net	2,536	(1,960)
Total other income (expense), net	5,611	(919)
Net loss	$ (93,612)	$ (120,407)
Net loss per share, basic (in USD per share)	$ (2.11)	$ (3.78)
Net loss per share, diluted (in USD per share)	$ (2.11)	$ (3.78)
Weighted-average common shares outstanding, basic (in shares)	44,320,050	31,819,006
Weighted-average common shares outstanding, diluted (in shares)	44,320,050	31,819,006

IMUX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 46,674	$ 106,745
Investments - other	0	9,629
Prepaid expenses and other current assets	5,860	9,490
Total current assets	52,534	125,864
Property and equipment, net	466	294
Right of use asset, net	1,299	1,552
Other long-term assets	0	43
Total assets	54,299	127,753
Current liabilities:
Accounts payable	5,099	4,281
Accrued expenses	18,664	7,986
Other current liabilities	966	810
Total current liabilities	24,729	13,077
Long-term liabilities:
Operating lease liabilities	639	992
Total long-term liabilities	639	992
Total liabilities	25,368	14,069
Commitments and contingencies (note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 130,000,000 shares authorized and 45,177,730 and 39,307,286 shares issued and outstanding at December 31, 2023 and 2022, respectively	4	4
Additional paid-in capital	436,060	427,925
Accumulated other comprehensive income	3,759	3,035
Accumulated deficit	(410,892)	(317,280)
Total stockholders’ equity	28,931	113,684
Total liabilities and stockholders’ equity	$ 54,299	$ 127,753

About Immunic Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

CEO	Dr. Daniel Vitt Ph.D.
WEBSITE	imux.com
INDUSTRY	Biotechnology
EMPLOYEES	75

Immunic Inc Frequently Asked Questions

What is the ticker symbol for Immunic Inc? What does IMUX stand for in stocks?

IMUX is the stock ticker symbol of Immunic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immunic Inc (IMUX)?

As of Wed Apr 17 2024, market cap of Immunic Inc is 109.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMUX stock?

You can check IMUX's fair value in chart for subscribers.

What is the fair value of IMUX stock?

You can check IMUX's fair value in chart for subscribers. The fair value of Immunic Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immunic Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMUX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immunic Inc a good stock to buy?

The fair value guage provides a quick view whether IMUX is over valued or under valued. Whether Immunic Inc is cheap or expensive depends on the assumptions which impact Immunic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMUX.

What is Immunic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, IMUX's PE ratio (Price to Earnings) is -1.17 and Price to Sales (PS) ratio is 3.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMUX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Immunic Inc's stock?

In the past 10 years, Immunic Inc has provided -0.45 (multiply by 100 for percentage) rate of return.